SubHero Banner

Mozobil® (plerixafor) – First-time authorized brand alternative

July 20, 2023 - Daiichi Sankyo announced the FDA approval of Vanflyta (quizartinib), in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.

Download PDF